BR112015013708A2 - polipeptídeo compreendendo uma proteína igf-1 humana, polinucleotídeo, composição farmacêutica e uso - Google Patents

polipeptídeo compreendendo uma proteína igf-1 humana, polinucleotídeo, composição farmacêutica e uso

Info

Publication number
BR112015013708A2
BR112015013708A2 BR112015013708A BR112015013708A BR112015013708A2 BR 112015013708 A2 BR112015013708 A2 BR 112015013708A2 BR 112015013708 A BR112015013708 A BR 112015013708A BR 112015013708 A BR112015013708 A BR 112015013708A BR 112015013708 A2 BR112015013708 A2 BR 112015013708A2
Authority
BR
Brazil
Prior art keywords
polypeptide
polynucleotide
protein
pharmaceutical composition
human igf
Prior art date
Application number
BR112015013708A
Other languages
English (en)
Other versions
BR112015013708B1 (pt
Inventor
Fornaro Mara
Zurini Mauro
Huber Thomas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015013708(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015013708A2 publication Critical patent/BR112015013708A2/pt
Publication of BR112015013708B1 publication Critical patent/BR112015013708B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "polipeptídeos de fator de crescimento semelhante a insulina estabilizados". esta invenção está no campo de modificações de igf-1. em particular, refere-se a polipeptídeos de igf-1 modificado e polipeptídeo de precursor de igf-1s modificado em que a clivagem de e-peptídeo é prevenida. a invenção da mesma forma refere-se ao uso de tais polipeptídeos para tratar doenças e distúrbios musculares.
BR112015013708-3A 2012-12-18 2013-12-16 Polipeptídeo compreendendo uma proteína igf-1 humana, seu uso, polinucleotídeo e composição farmacêutica BR112015013708B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
US61/738,475 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Publications (2)

Publication Number Publication Date
BR112015013708A2 true BR112015013708A2 (pt) 2017-11-14
BR112015013708B1 BR112015013708B1 (pt) 2022-10-18

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013708-3A BR112015013708B1 (pt) 2012-12-18 2013-12-16 Polipeptídeo compreendendo uma proteína igf-1 humana, seu uso, polinucleotídeo e composição farmacêutica

Country Status (37)

Country Link
US (1) US10167329B2 (pt)
EP (2) EP2935320B1 (pt)
JP (1) JP6499080B2 (pt)
KR (1) KR102182523B1 (pt)
CN (1) CN105121462B (pt)
AP (1) AP2015008440A0 (pt)
AU (1) AU2013365796B2 (pt)
BR (1) BR112015013708B1 (pt)
CA (1) CA2894976C (pt)
CL (1) CL2015001708A1 (pt)
CR (2) CR20200079A (pt)
CU (1) CU24308B1 (pt)
CY (1) CY1122309T1 (pt)
DK (1) DK2935320T3 (pt)
EA (1) EA034356B1 (pt)
EC (1) ECSP15031046A (pt)
ES (1) ES2756330T3 (pt)
GT (1) GT201500168A (pt)
HK (1) HK1212712A1 (pt)
HR (1) HRP20191965T1 (pt)
HU (1) HUE047386T2 (pt)
IL (1) IL239387A0 (pt)
LT (1) LT2935320T (pt)
MA (1) MA38153B1 (pt)
MX (1) MX363021B (pt)
MY (1) MY174820A (pt)
NZ (1) NZ708091A (pt)
PE (1) PE20151612A1 (pt)
PH (1) PH12015501271A1 (pt)
PL (1) PL2935320T3 (pt)
PT (1) PT2935320T (pt)
RS (1) RS59545B1 (pt)
SA (1) SA515360603B1 (pt)
SG (1) SG11201503782PA (pt)
SI (1) SI2935320T1 (pt)
TN (1) TN2015000182A1 (pt)
WO (1) WO2014097116A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271265A1 (en) * 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
MX2018010470A (es) * 2016-03-04 2018-12-06 Shire Human Genetic Therapies Proteinas de fusion folistatina-fc recombinantes y su uso en el tratamiento de la distrofia muscular de duchenne.
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
US10821155B2 (en) * 2018-06-27 2020-11-03 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
PT1141015E (pt) * 1999-01-06 2009-10-13 Genentech Inc Variantes mutantes do factor de crescimento do tipo insulina (igf)i
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
JP4988599B2 (ja) 2005-01-07 2012-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−１融合ポリペプチドおよびその治療的使用
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
JP2009539805A (ja) 2006-06-09 2009-11-19 ノバルティス アクチエンゲゼルシャフト 安定化されたインスリン様増殖因子ポリペプチド
CN101466399B (zh) * 2006-06-09 2015-05-13 诺华股份有限公司 稳定的胰岛素样生长因子多肽
BRPI0821311B1 (pt) 2007-12-21 2018-09-18 Novartis Ag Ácido nucleico de vetor linearizado, método para produção de uma célula hospedeira de mamífero compreendendo o referido ácido, e método para produção de um polipetídeode interesse
LT2424895T (lt) 2009-04-27 2017-12-27 Novartis Ag Kompozicijos ir būdai, skirti raumenų augimo spartinimui
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
EP2935319B1 (en) 2012-12-18 2019-04-24 Novartis AG Production of therapeutic proteins in genetically modified mammalian cells
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Also Published As

Publication number Publication date
AU2013365796B2 (en) 2017-03-30
PT2935320T (pt) 2019-11-15
MA38153A1 (fr) 2016-06-30
DK2935320T3 (da) 2019-11-18
US10167329B2 (en) 2019-01-01
HK1212712A1 (zh) 2016-06-17
CR20200079A (es) 2020-03-21
CU24308B1 (es) 2018-01-10
CN105121462B (zh) 2019-08-02
US20150329614A1 (en) 2015-11-19
MA38153B1 (fr) 2018-06-29
TN2015000182A1 (en) 2016-10-03
MY174820A (en) 2020-05-17
CA2894976C (en) 2022-10-04
KR102182523B1 (ko) 2020-11-25
CN105121462A (zh) 2015-12-02
MX363021B (es) 2019-03-05
AP2015008440A0 (en) 2015-05-31
ECSP15031046A (es) 2019-03-29
JP2016501025A (ja) 2016-01-18
CU20150064A7 (es) 2016-02-29
WO2014097116A1 (en) 2014-06-26
MX2015007932A (es) 2015-10-05
EP2935320A1 (en) 2015-10-28
PL2935320T3 (pl) 2020-03-31
CR20150324A (es) 2015-08-10
CY1122309T1 (el) 2021-01-27
EA201591165A1 (ru) 2015-11-30
PH12015501271B1 (en) 2015-08-24
KR20150095879A (ko) 2015-08-21
SA515360603B1 (ar) 2020-07-26
GT201500168A (es) 2016-01-21
EP2935320B1 (en) 2019-08-21
BR112015013708B1 (pt) 2022-10-18
AU2013365796A1 (en) 2015-05-28
ES2756330T3 (es) 2020-04-27
EA034356B1 (ru) 2020-01-30
PH12015501271A1 (en) 2015-08-24
SG11201503782PA (en) 2015-06-29
LT2935320T (lt) 2019-11-11
HUE047386T2 (hu) 2020-04-28
NZ708091A (en) 2018-03-23
JP6499080B2 (ja) 2019-04-10
SI2935320T1 (sl) 2019-12-31
IL239387A0 (en) 2015-07-30
EP3626735A1 (en) 2020-03-25
CA2894976A1 (en) 2014-06-26
HRP20191965T1 (hr) 2020-01-24
CL2015001708A1 (es) 2015-08-28
RS59545B1 (sr) 2019-12-31
PE20151612A1 (es) 2015-11-19

Similar Documents

Publication Publication Date Title
BR112015013708A2 (pt) polipeptídeo compreendendo uma proteína igf-1 humana, polinucleotídeo, composição farmacêutica e uso
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
BR112016008540A2 (pt) análogos de glucagon
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
BR112012033225A2 (pt) análogos do glucagon
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
ECSP13012618A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
CL2008000348A1 (es) Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
BR112015029611A2 (pt) composições para uso em ruptura de cartilagem
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
CL2013002673A1 (es) Composicion que comprende un polipéptido aislado con actividad inhibidor de nav1.3 y nav1.7; composicion farmacéutica que comprende la composicion antes dicha; metodo para tratar dolor.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
ES2399651T8 (es) Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
BR112016014042A2 (pt) composições e métodos para tratar deposição de tecido adiposo
CL2007002643A1 (es) Compuestos derivados de 5-fenil-nicotinamida, moduladores del receptor de cb1; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de la nutricion, diabetes tipo ii y dependencia de sustan
BR112013032088A2 (pt) "polipeptídeo, composição farmacêutica e seu uso"
BR112018003455A2 (pt) composição ou composição farmacêutica e uso da composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2013, OBSERVADAS AS CONDICOES LEGAIS